Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This stock hit a low of $6.00 pre-market. I watched it move back up fast to $7.00. Got an order in for 6.80 which was filled and sold at $7.12 for a nice profit. I flipped this a few times during the day.
This stock is a perfect ATM for sure. It is rare that you are lucky enough to come across a mover like this. Just play the movement and you can make a fortune.
I was surprised it even got close to $8.00 plus again. I would not give up on this one.
Press releases indicates "Orphan Designation", FDA Orphan Approval Status; Not Approved for Orphan Indication.
Innocent Semantics? Partial Story?
http://www.streetinsider.com/Corporate+News/CanTx+Granted+FDA+Orphan+Drug+Designation+for+Cantrixil+%28NVGN%29+/10476279.html
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=474815
Search Orphan Drug Designations and Approvals
Developing Products for Rare Diseases & Conditions4 -
Orphan Designation Search
Generic Name: cantrixil
Trade Name: n/a
Date Designated: 04-20-2015
Orphan Designation: Treatment of ovarian cancer
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Sponsor: CanTx, Inc.
5 Science Park
3rd Floor
New Haven, CT 06511
Cantrixil--Orphan Drug Designation
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=474815
Halt until Thursday? This appears to be current news from AU.
Tue 21 Apr 2015 13:12 AAP – 2 hours 29 minutes ago
https://au.finance.yahoo.com/news/novogen-poised-capital-raising-003707394.html
Cancer therapy biotech Novogen has placed its shares in a trading halt ahead of an expected announcement about a capital raising.
Novogen says it is preparing an announcement about a placement of ordinary shares and attaching options, along with an offer of ordinary shares.
It expects the halt to remain in place until Thursday at the latest.
Meanwhile, the biotech also says animal trials of its experimental anti-cancer drug Cantrixil have shown that it can prevent ovarian cancer tumours from returning in mice.
Here comes new shares.... ?
Tue 21 Apr 2015 13:14 AAP – 1 hour 8 minutes ago
https://au.finance.yahoo.com/news/novogen-taps-investors-30-5m-015812296.html
Is this what others have said happens with NVGN... up goes the price on multiple PRs, add new shares into the pot.... repeat? I have only watched NVGN for a short time and only read a handful of posts... so it's really an honest question.
Is this a repeat of history for those who have been involved for 6-12+ months?
Here is the PR:
Novogen is tapping investors for $30.5 million as it prepares to enter a major growth phase fuelled by development of its cancer-fighting drugs.
The biotech is carrying out a $15.5 million share placement with institutional investors and issuing another $15 million worth of shares to existing shareholders.
Chief executive Graham Kelly says Novogen will use the money raised to help pay for research programs into the development of the company's drug pipeline.
"The company is about to enter a significant growth phase," he said in a statement on Tuesday.
"I believe that the company has the intellectual property and the management expertise to achieve its goal of becoming a major player in the international biotechnology sector, and the fund-raising that we have announced today is key to that."
As part of its fundraising, Novogen is issuing 51 million fully-paid ordinary shares with attaching options to institutional investors in the United States.
Existing shareholders will also be able to take part in a one-for-six non-renounceable rights issue offer of fully-paid ordinary shares.
Novogen shares were 12.5 per cent, or 30 per cent, lower at 29 cents at 1152 AEST.
Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer
http://www.prnewswire.com/news-releases/cantrixil-highly-successful-in-preventing-growth-of-chemo-resistant-ovarian-cancer-300068344.html
$NVGN recent news/filings
bullish
gap up
## source: finance.yahoo.com
Thu, 09 Apr 2015 20:22:00 GMT ~ Novagen (NVGN) Stock Spiked Today on Melanoma Treatment Study Results
read full: http://www.thestreet.com/story/13107625/1/novagen-nvgn-stock-spiked-today-on-melanoma-treatment-study-results.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Thu, 09 Apr 2015 03:06:00 GMT ~ Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma
[PR Newswire] - NVGN: NASDAQ), today announced that studies conducted at The University of Queensland Diamantina Institute (UQDI) revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status. The significance of this finding lies in the fact that melanoma is associated with a variety of mutations, with those to the BRAF gene being the most prominent. A mutation to the BRAF gene occurs in about half of all melanoma patients and two drugs that target that mutation (vemurafenib and dabrafenib) have come to market in recent times. No targeted therapy exists for the 50% of melanoma patients whose tumors do not have the BRAF mutation.
read full: http://finance.yahoo.com/news/australian-studies-confirm-anisina-potential-030600994.html
*********************************************************
Thu, 02 Apr 2015 02:49:00 GMT ~ Novogen Engages Leading US Investor Relations Firm
[PR Newswire] - SYDNEY, April 2, 2015 /PRNewswire/ -- Novogen Ltd (ASX:NRT NASDAQ:NVGN) today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program ...
read full: http://finance.yahoo.com/news/novogen-engages-leading-us-investor-024900307.html
*********************************************************
Mon, 30 Mar 2015 08:52:13 GMT ~ Novogen shares surge on drug data
[AAP] - Shares in drug discoverer Novogen have surged after the company said its experimental anti-cancer drug Cantrixil killed human ovarian stem cells. Novogen, which is listed on the Australian Securities Exchange ...
read full: http://au.finance.yahoo.com/news/novogen-shares-surge-drug-data-002519888.html
*********************************************************
Mon, 30 Mar 2015 00:53:00 GMT ~ Yale University and Novogen Release Data on Cantrixil Mode of Action
[PR Newswire] - NASDAQ:NVGN) and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA. In both in vitro and in animal studies, Cantrixil, has proved highly effective at killing human ovarian stem (tumor-initiating) cells, cells that otherwise are highly resistant to standard of care cytotoxic drugs and which generally are believed to be responsible for diseases recurrence following initial therapy. In addition, Cantrixil blocks the survival pathway pERK. The combination of these two cellular effects (down-regulation of pro-survival and up-regulation of pro-death pathways) provides a unique advantage to target chemo-resistant cancer stem cells.
read full: http://finance.yahoo.com/news/yale-university-novogen-release-data-005300956.html
*********************************************************
$NVGN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NVGN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NVGN/company-info
Ticker: $NVGN
OTC Market Place: Not Available
CIK code: 0001075880
Company name: Novogen Ltd.
Company website: http://www.novogen.com
Incorporated In: Australia
$NVGN share structure
## source: otcmarkets.com
Market Value: $584,452 a/o Apr 14, 2015
Shares Outstanding: 2,018,137 a/o Jan 03, 2011
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$NVGN extra dd links
Company name: Novogen Ltd.
Company website: http://www.novogen.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NVGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NVGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NVGN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/news - http://finance.yahoo.com/q/h?s=NVGN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NVGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NVGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NVGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Novogen+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Novogen+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Novogen+Ltd.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.novogen.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.novogen.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.novogen.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NVGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001075880&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NVGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NVGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NVGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NVGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NVGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NVGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NVGN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NVGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NVGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NVGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NVGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NVGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NVGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NVGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NVGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NVGN
$NVGN DD Notes ~ http://www.ddnotesmaker.com/NVGN
NVGN 8.5 highs pre, nasty rip squeeze
NVGN 7.7 +6% showing gappa action. Squeeze on
* * $NVGN Video Chart 04-14-15 * *
Link to Video - click here to watch the technical chart video
Still holding my few thousand shares...hopefully another announcement tonight or by next Monday...looking at NRT tonight on ASX.
Over 7 now on no started trials. Great trading all,Strik
can anyone point me to a calendar of upcoming catalysts for this? would be much appreciated.
Big reason to buy (at a lower price) is CEO. Dr. Kelly used compounds on self and controlled his cancer,Strik
The management in place right now will take this into the 30s once phase one is well under way. Phase one will not only show safety but a very high success rate on effectiveness,Strik PS: within 14 months IMO
* * $NVGN Video Chart 04-09-15 * *
Link to Video - click here to watch the technical chart video
MONSTER NVGN Gap up open and $15,000, one day, overnight win. Swing trader Jason Bond hit a HUGE $15,000 win in NVGN today. Wow! Details of what the pattern was he saw and why he bought NVGN Jason Bond Hits $15,000 50% Win Overnight In NVGN
Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma
Source: PR Newswire (US)
SYDNEY, April 9, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen (NRT:ASX; NVGN: NASDAQ), today announced that studies conducted at The University of Queensland Diamantina Institute (UQDI) revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.
The significance of this finding lies in the fact that melanoma is associated with a variety of mutations, with those to the BRAF gene being the most prominent. A mutation to the BRAF gene occurs in about half of all melanoma patients and two drugs that target that mutation (vemurafenib and dabrafenib) have come to market in recent times. No targeted therapy exists for the 50% of melanoma patients whose tumors do not have the BRAF mutation. But even where a response is obtained with a BRAF-inhibitor, resistance typically develops within a year of treatment. Therefore the development of a drug that kills melanoma cells irrespective of their BRAF or any other mutational status has become an urgent clinical imperative.
Novogen believes that Anisina represents a significant potential opportunity to meet this need.
UQDI screened Anisina against a panel of melanoma cells obtained from patients and which represented the spectrum of mutations (BRAF, NRAS and c-KIT) commonly found in the community. Anisina was uniformly cytotoxic to the panel of cells, regardless of their mutational status. Importantly, Anisina showed a high level of specificity to cancer cells, with toxicity against normal melanocytes requiring a four-fold drug level.
Anisina is an anti-tropomyosin compound that targets the cytoskeleton of the cancer cells. It is being brought into the clinic for the treatment of cancers as a companion drug for the anti-mitotic family of drugs…the taxanes and vinca alkaloids. The rationale is that the use of Anisina (targeting the microfilaments) in combination with anti-mitotic drugs (targeting the microtubules), provide comprehensive destruction of the two key parts of the cancer cell's skeleton resulting in a 20-fold increase in the anti-cancer effect of either drug family alone.
Anisina is being brought into the clinic in early-2016 for the treatment of solid cancers, with late-stage melanoma and prostate cancer in adults and neuroblastoma in children being three key target indications. The current results give strength to the aim of conducting a clinical study in patients with late-stage melanoma using a combined treatment of Anisina and vincristine.
Nikolas Haass MD PhD and Brian Gabrielli PhD conducted the research studies.
Dr Haass said, "These findings from the preliminary screen with Anisina are exciting. Finding a compound that is equally effective against a wide panel of melanoma cell types irrespective of the genetic background has been a long-held goal. The University of Queensland Diamantina Institute is pleased to be part of the effort to bring this new drug candidate into the clinic."
Justine Stehn PhD, Novogen Anti-Tropomyosin Program Director, said, "Melanoma is a notoriously difficult cancer to treat. The standard first-line cytotoxic drugs such as the taxanes and vinca alkaloids have little anti-cancer effect."
"But we see a 20-fold increase in the cancer killing effect of these drugs when combined with Anisina. We have demonstrated this combination effect with vincristine in prostate cancer cells, neuroblastoma cells, and now melanoma cells. The idea that we now have a means of making melanoma cells respond to potent anti-cancer drugs such as vincristine is an exciting development for patients with melanoma."
Graham Kelly PhD, Novogen Group CEO, said, "These results support our belief that Anisina has the potential to become one of the most widely used anti-cancer drugs across the full spectrum of cancer. In conjunction with our clinical advisors, we have a clinical strategy laid out which we intend to prosecute all the way through to achieving regulatory approval."
$NVGN recent news/filings
bullish
quick trade
## source: finance.yahoo.com
Thu, 02 Apr 2015 02:49:00 GMT ~ Novogen Engages Leading US Investor Relations Firm
[PR Newswire] - SYDNEY, April 2, 2015 /PRNewswire/ -- Novogen Ltd (ASX:NRT NASDAQ:NVGN) today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program ...
read full: http://finance.yahoo.com/news/novogen-engages-leading-us-investor-024900307.html
*********************************************************
Mon, 30 Mar 2015 08:52:13 GMT ~ Novogen shares surge on drug data
[Other] - Shares in drug discoverer Novogen have surged after the company said its experimental anti-cancer drug Cantrixil killed human ovarian stem cells. Novogen, which is listed on the Australian Securities Exchange ...
read full: http://au.finance.yahoo.com/news/novogen-shares-surge-drug-data-002519888.html
*********************************************************
Mon, 30 Mar 2015 00:53:00 GMT ~ Yale University and Novogen Release Data on Cantrixil Mode of Action
[PR Newswire] - NASDAQ:NVGN) and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA. In both in vitro and in animal studies, Cantrixil, has proved highly effective at killing human ovarian stem (tumor-initiating) cells, cells that otherwise are highly resistant to standard of care cytotoxic drugs and which generally are believed to be responsible for diseases recurrence following initial therapy. In addition, Cantrixil blocks the survival pathway pERK. The combination of these two cellular effects (down-regulation of pro-survival and up-regulation of pro-death pathways) provides a unique advantage to target chemo-resistant cancer stem cells.
read full: http://finance.yahoo.com/news/yale-university-novogen-release-data-005300956.html
*********************************************************
Wed, 18 Mar 2015 11:00:00 GMT ~ Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study
[PR Newswire] - SYDNEY, March 18, 2015 /PRNewswire/ -- Novogen announced on 18th March, 2015 that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell's cytoskeleton can deliver a powerful anti-cancer effect. Dr Kelly was interviewed by Channel 7 health reporter, Dr Andrew Rochford about Anisina's potential. To view the interview click here…… or visit the Novogen website. The most commonly used drugs in chemotherapy target the cytoskeleton by destabilising one of its two key components, the microtubules. The rationale behind the development of Anisina was that the anti-mitotic drugs only do half the job, because they leave the other major component of the cytoskeleton, the microfilaments, intact.
read full: http://finance.yahoo.com/news/potential-anisina-become-major-chemotherapy-110000656.html
*********************************************************
Tue, 10 Mar 2015 04:28:00 GMT ~ Sky News, Helen Dalley interviews Dr Graham Kelly
[PR Newswire] - SYDNEY, March 10, 2015 /PRNewswire/ -- Novogen Ltd (ASX: 'NRT'; Nasdaq: 'NVGN') CEO , Dr Graham Kelly, PhD, was interviewed by Sky News ' , Helen Dalley about the breakthrough brain cancer drug being developed ...
read full: http://finance.yahoo.com/news/sky-news-helen-dalley-interviews-042800464.html
*********************************************************
$NVGN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NVGN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NVGN/company-info
Ticker: $NVGN
OTC Market Place: Not Available
CIK code: 0001075880
Company name: Novogen Ltd.
Company website: http://www.novogen.com
Incorporated In: Australia
$NVGN share structure
## source: otcmarkets.com
Market Value: $332,589 a/o Apr 06, 2015
Shares Outstanding: 2,018,137 a/o Jan 03, 2011
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$NVGN extra dd links
Company name: Novogen Ltd.
Company website: http://www.novogen.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NVGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NVGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NVGN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/news - http://finance.yahoo.com/q/h?s=NVGN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NVGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NVGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NVGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Novogen+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Novogen+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Novogen+Ltd.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.novogen.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.novogen.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.novogen.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NVGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001075880&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NVGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NVGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NVGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NVGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NVGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NVGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NVGN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NVGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NVGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NVGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NVGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NVGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NVGN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NVGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NVGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NVGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NVGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NVGN
$NVGN DD Notes ~ http://www.ddnotesmaker.com/NVGN
Also make you loco I'll see you soon back in the 3sss.
NVGN- Novogen- One co which can make you retire!!!!
Buying and adding all I can here, will not last
The good news just keeps coming for us!!
Yale University and Novogen Release Data on Cantrixil Mode of Action
Key data confirming Cantrixil kills ovarian cancer stem cells
Unique action of inhibiting pro-survival mechanisms and promoting pro-death mechanisms
PR Newswire Novogen Ltd
13 minutes ago
????
SYDNEY, March 30, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN) and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.
In both in vitro and in animal studies, Cantrixil, has proved highly effective at killing human ovarian stem (tumor-initiating) cells, cells that otherwise are highly resistant to standard of care cytotoxic drugs and which generally are believed to be responsible for diseases recurrence following initial therapy. Researchers have been keen to understand how the active ingredient in Cantrixil, TRXE-002, is able to achieve this effect where other drugs have failed.
The data shows that Cantrixil specifically activates the JNK-Jun pathway leading to mitochondrial damage and the induction of genes associated with cell death (apoptosis). In addition, Cantrixil blocks the survival pathway pERK. The combination of these two cellular effects (down-regulation of pro-survival and up-regulation of pro-death pathways) provides a unique advantage to target chemo-resistant cancer stem cells.
Cantrixil is due to enter its first-in-man study in late-2015. The study will enroll patients with the terminal condition, malignant ascites, associated with late-stage abdominal carcinomatosis of various types of cancer, but mainly targeting ovarian cancer and colo-rectal cancer.
About Cantrixil
Cantrixil is a cyclodextrin envelope containing the active ingredient, TRXE-002. The construct has been designed as an intra-cavity chemotherapy to be injected directly into the peritoneal and pleural cavities without causing local irritation or toxicity. Its purpose is to achieve high drug levels in the environment in which the cancer is spreading through the migration of the cancer stem cells are spreading. The ultimate primary indication of Cantrixil to be sought is first-line therapy of early-stage cancers of the abdominal cavity (eg. ovarian, uterine, colo-rectal and gastric carcinomas). Cantrixil will enter the clinic in later-stage cancers where the abdominal carcinomatosis has resulted in the terminal condition of malignant ascites.
Cantrixil is owned by CanTx, Inc.
About TRXE-002
TRXE-002 is a small molecule cytotoxic belonging to a family of compounds whose anti-cancer function is based on various biological effects including inhibition of trans-membrane electron-transfer mechanisms. TRXE-002 is pan anti-cancer acting, resulting in caspase-dependent apoptosis of both stem cell-like cancer cells and their daughter cancer cells. The compound has a high therapeutic index with little cytotoxic effect on non-tumor cells.
About CanTx, Inc.
CanTx is a joint venture company between Novogen and Yale University. Novogen has licensed the drug candidate, TRXE-002, to CanTx for use in Cantrixil. CanTx is based in New Haven, CT.
Further information is available on www.can-tx.com
About Novogen Limited
Novogen is a public, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, but with particular activity against the cancer stem (tumor-initiating) cell.
The ATM compounds target the micro-filament component of the cancer cell's cytoskeleton and have been designed to combine with anti-microtubule drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.
The Company pipeline comprises two SBP drug candidates (TRXE-002, TRXE-009) and one ATM drug candidate (Anisina).
Further information is available on our website www.novogen.com
For more information please contact:
Corporate Contact
Dr. Graham Kelly
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100
Media Enquiries
Cristyn Humphreys
Chief Operating Officer
Novogen Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472 4111
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "appear," "intends," "hopes," "anticipates," "believes," "could," "should," "would," "may," "target," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, Cantrixil and TRXE-002, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to Cantrixil and TRXE-002, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, Cantrixil and TRXE-002, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil and TRXE-002, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
oh,ok that makes sense
Each share here(NVGN) is equal to 25 (NRT)shares in Australia.. So there are well over 200 million shares of Novogen in the market place.
why is the shareprice at .21 Australian and dollars here?
ok good,thankyou very much
If you want more research on NVGN , go to ... Hotcopper.com au / .... and Australian stock code for NVGN is NRT... Good knowledge from some posters ...some have been on NRT longer than me .. Examples are Applefoot, rrodd , moosey , neg, Stayso, and Kate... Good luck, Strik
It may drop below 3 in the next 2 months due to inactivity. That said it may not . I'll try to buy below $3 and if I'm not able to I'll buy up to $5 per share once Phase one begins. I've followed Dr. K for over 20 years and he will have no trouble bringing his compounds to Phase 3 and no problem raising funds for trials and partners for NVGN. Last go around he capped out his company above 600 million market cap before unforeseen travesties occurred. In my eyes Dr. K has already proven his compounds will be welcomed worldwide . All my opinion and I will be a large holder again in the very near future GLA,, Strik
big bucks come during commercialization if the phase 1,2,3 work the way they should
hard to say because of too many factors like Offerings?
there aren't many shorts to squeeze= http://www.finviz.com/quote.ashx?t=NVGN
But if the SS doesn't grow its small enough to go big with additional good news!
-imo
NVGN PIPELINE:
http://www.novogen.com/programs.html
in your opinion where can this move too?
OUT.....WEEEEEEEEEEE! THAT WAS FUN
This low floater can run!
Watching and thanks
Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study
Now - DJNF
SYDNEY, March 18, 2015 /PRNewswire/ -- Novogen announced on 18(th) March, 2015 that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell's cytoskeleton can deliver a powerful anti-cancer effect.
Dr Kelly was interviewed by Channel 7 health reporter, Dr Andrew Rochford about Anisina's potential. To view the interview click here... or visit the Novogen website.
The cytoskeleton (cell skeletal structure) is a common and validated target for anti-cancer therapy. The most commonly used drugs in chemotherapy target the cytoskeleton by destabilising one of its two key components, the microtubules. These drugs are known as 'anti-mitotics' and include the taxanes (paclitaxel, docetaxel) and the vinca alkaloids (vincristine, vinblastine). Collectively, these anti-mitotics have dominated chemotherapy for the past 30 years and look set to do so for many years to come.
The rationale behind the development of Anisina was that the anti-mitotic drugs only do half the job, because they leave the other major component of the cytoskeleton, the microfilaments, intact. It was reasoned that this half-complete destruction of the cytoskeleton by the anti-mitotic drugs accounted for their low rate of patient response for many tumor types and for the generally short-term response to therapy. Anisina was developed specifically to destroy the microfilaments and to work in combination with the anti-mitotic drugs to deliver comprehensive destruction of the cancer cell's architecture.
Anisina targets a specific protein known as tropomyosin Tpm3.1 (previously known as Tm5NM1). Tpm3.1 is a protein that provides structural integrity to the microfilaments of a cell. It is present in both normal cells and cancer cells, the difference being that cancer cells have an increased reliance on this form of tropomyosin to survive.
It has been announced previously that anti-tropomyosin drugs in combination with anti-mitotic drugs boost the cancer-killing ability of a drug such as vincristine 20-fold in vitro against neuroblastoma cancer cells.
The next crucial step was to confirm that this powerful combined anti-cancer effect was transferable to animals. The study reported today confirms this.
This proof of concept study was done as part of the Children's Oncology Drug Alliance (CODA) involving Australian charity, The Kids' Cancer Project (Sydney), The University of New South Wales (Sydney), The Nationwide Children's Hospital (Columbus, Ohio), and Novogen. The studies were conducted using cancer cells derived from children who had developed neuroblastoma.
The full details of these studies will be presented at the Eighth Annual Cancer Molecular Therapeutics Research Association (CMTRA) meeting in the USA in July of this year.
Justine Stehn PhD, Novogen Anti-Tropomyosin Program Director, said, "This was the crucial step we needed to bring Anisina into the clinic. We now are proceeding to bring Anisina into the clinic in 2016 into both adults and children. In adults we will be looking to use Anisina to potentiate the anti-cancer effect of anti-mitotics in cancers such as prostate, ovarian, lung, breast, colorectal and haematological cancers, as well as in cancers such as melanoma where anti-mitotics currently show little benefit."
"But what particularly excites us from a CODA perspective is the promise that this technology holds in being able to achieve a potent anti-cancer effect in children where anti-mitotics currently are widely used, but being able to use lower dosages of anti-mitotics that hopefully will lower the risk of leaving children with side-effects with life-long consequences."
Graham Kelly PhD, Novogen CEO and Executive Chairman said, "From the outset, the anti-tropomyosin technology platform has held the promise of delivering a major new chemotherapy, one that we saw becoming a standard companion drug to the most commonly-used drugs in chemotherapy. Today's announcement just serves to reinforce that promise."
"The promise of Anisina is that it is not a drug limited to working in a proportion of patients with a particular form of cancer, or one that is reliant on the over-expression of certain functions such as immune checkpoints or pro-survival mechanisms. Its promise lies in its ability to make the most widely-used chemotherapy drugs work better and safer in more forms of cancer and in more patients. Our objective is to see Anisina become one of the most widely used drugs in chemotherapy
9M float > could be a huge upside mover today!
THANK YOU SUH!!!! NVGN
Followers
|
31
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
396
|
Created
|
10/19/07
|
Type
|
Free
|
Moderators |
Dr Graham Kelly, Executive Chairman
Novogen Enquiries
Dr Graham Kelly
CEO Novogen Group
Graham.Kelly@novogen.com
+(61 2) 9472 4100
Media Enquiries
Cristyn Humphreys
Operations Manager Novogen Group
Cristyn.Humphreys@Novogen.com
+ 61 2 9472 4111 / + 61 499 088 482
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |